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Summary
We have developed a nonheuristic genome topography scan (GTS) algorithm to characterize the
patterns of genomic alterations in human glioblastoma (GBM), identifying frequent p18INK4C and
p16INK4A codeletion. Functional reconstitution of p18INK4C in GBM cells null for both p16INK4A and
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tp18INK4C resulted in impaired cell-cycle progression and tumorigenic potential. Conversely, RNAi-
mediated depletion of p18INK4C in p16INK4A-deficient primary astrocytes or established GBM cells
enhanced tumorigenicity in vitro and in vivo. Furthermore, acute suppression of p16INK4A in primary
astrocytes induced a concomitant increase in p18INK4C. Together, these findings uncover a feedback
regulatory circuit in the astrocytic lineage and demonstrate a bona fide tumor suppressor role for
p18INK4C in human GBM wherein it functions cooperatively with other INK4 family members to
constrain inappropriate proliferation.
Keywords
CELLCYCLE
SIGNIFICANCE
Understanding the molecular basis of human cancer and, thereby, targeting the genetic
defects in a rational manner requires a comprehensive knowledge of not only the driving
pathogenetic lesions but also their interactions. Using a newly developed algorithm that
enables the analysis of copy number profiles based on focality, amplitude, and recurrence
of the genomic events, we uncovered a codeletion pattern among closely related INK genes
in the GBM oncogenome, challenging the prevailing single-hit model of RB pathway
inactivation. Elucidation of the molecular basis underlying this codeletion pattern
revealed a backup tumor suppressor role for p18INK4C in the setting of p16INK4A deletion,
thus expanding our understanding of human GBM and compensation among INK family
members in human tumors.
Introduction
GBM, the most common primary brain tumor in adults, is neurologically destructive and
maintains dismal responses to virtually all therapeutic modalities. The pathobiology of GBM
is characterized by rapid proliferation as well as widespread invasion, robust angiogenesis,
apoptosis resistance, and florid necrosis (Furnari et al., 2007). On the molecular level, GBM
is characterized by coactivation of receptor tyrosine kinases (Huang et al., 2007; Stommel
et al., 2007), activation of PI3K-AKT signaling (Li et al., 1997a; Stambolic et al., 1998), and
loss of p53 and RB tumor suppressor pathway function (Furnari et al., 2007).
Disruption of the RB pathway appears to be an obligate event in tumorigenesis and is achieved
primarily through either deletion/mutation of RB, amplification of the G1 cyclin-dependent
kinases 4 or 6 (CDK4/6), or deletion/silencing of the G1 CDK inhibitor (CKI), CDKN2A
(p16INK4A). In individual human tumor specimens, these principal components of the pathway
—RB-CDK4/6-p16INK4A—are reported to be targeted in a mutually exclusive manner (Sherr
and McCormick, 2002) consistent with their overlapping functions in regulating the G1-S
transition of the cell cycle (Massague, 2004). However, recent data in the mouse have
challenged this notion of exclusivity. Sharpless and colleagues reported that combined
germline nullizygosity for p16Ink4a and its related family member p18Ink4c facilitated the
development of pituitary tumors in the mouse (Ramsey et al., 2007). Berns and colleagues
showed enhanced tumorigenicity and expanded tumor spectrum in mice null for p15Ink4b and
p16Ink4a/Arf, compared to p16Ink4a/Arf alone (Krimpenfort et al., 2007). While these genetic
data in the mouse have suggested cooperation and/or compensation among members of the
Ink4 family of CKI, the relevance to human cancers of these findings in the mouse has not
been established.
The recalcitrant nature of GBM and emerging evidence for genes and genomic loci governing
response to both targeted and conventional therapy (Cahill et al., 2007; Hunter et al., 2003;
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tMellinghoff et al., 2005) have motivated efforts to more fully define the genetics of GBM.
Previous conventional and array-based comparative genomic hybridization (array-CGH)
profiles have revealed numerous recurrent regional copy number aberrations (CNAs) in GBM
(Kotliarov et al., 2006; Nigro et al., 2005; Ichimura et al., 2006; Korshunov et al., 2006; Lee
et al., 2006; Liu et al., 2006; Mulholland et al., 2006; Rossi et al., 2005). The large numbers
of CNAs detected by array-CGH and the resulting long lists of resident genes have highlighted
the need for a systematic objective prioritization approach designed to separate true CNA target
genes from bystanders.
Here, we report the development of a nonheuristic genome topography scan (GTS) algorithm
to define and rank genomic regions exhibiting significant CNAs based on genome-wide array-
CGH profiles of primary GBM samples and cell lines. In addition to the expected GBM
signature alterations, GTS identified many CNAs not previously implicated in GBM
development, uncovered genomic codeletion of two highly related G1 CKIs, p18INK4C and
p16INK4A, in human GBM tumors and cell lines, leading to discovery and validation of a
previously unappreciated cell-cycle regulatory circuit in the astrocytic lineage.
Results
GTS Defines Regions of Interest Encompassing Focal and Recurrent CNAs
To identify novel GBM-relevant genes, we performed high-resolution, oligo-based array-CGH
profiling to determine the genome-wide CNA patterns of 28 pathologically verified primary
Grade IV glioma (GBM) specimens and 18 established glioma cell lines (Table S1 available
online). Using a rule-based algorithm to define minimal common regions (MCRs) of CNAs
based on amplitude, width, and recurrence of CNAs (Aguirre et al., 2004; Carrasco et al., 2006;
Tonon et al., 2005), we readily identified the signature genomic events known previously for
GBM (e.g., EGFR amplification or CDKN2A deletion) as well as many previously
uncharacterized alterations (Table S2). In view of the large number of CNAs and the
complexity of overlap across samples, we developed a nonheuristic methodology, genome
topography scanning (GTS), to more rigorously define and rank genomic regions based on the
amplitude, width, and recurrence of a CNA.
In two dimensions, array-CGH measures the relative changes in chromosomal copy number
as a deviation from the baseline diploid state at every interrogated position along the genome.
As such, it captures both the amplitude and width of a CNA in a tumor. Since the frequency
of a CNA is believed to be a strong indicator of potential biological significance, recurrence
is considered the third dimension for defining the topography of a CNA in GTS. We derived
two indices to capture these three major features describing the topography of any given CNA.
First, the Aberration amplitude and Recurrence Index (ARI) measures the composite
contribution of the copy number value (log2 amplitude of the CNA) and the frequency of the
aberration (recurrence) at a genomic position (See Experimental Procedures). Second, the
Aberration Focality Index (AFI) weights the amplitude and recurrence inversely by an estimate
of the number of genetic elements spanned by the CNA (see Experimental Procedures). Thus,
the AFI assigns to each region in the genome a measure of the likelihood of any genetic element
within the region representing the true target of genomic alterations across a sample set. With
ARI and AFI calculated for each genomic position, we represented the GBM oncogenome in
a typical skyline profile, with ARI on the vertical axis and AFI on the color-scale (Figure 1A).
Not surprisingly, salient events in red (high AFI) with high amplitude and recurrence (high
ARI) coincide with known common, high-amplitude and focal CNAs in GBM, including
EGFR, PDGFRA, MET, PTEN, and CDKN2A/B (p16INK4A/p15INK4B).
Next, we generated two-dimensional GTS plots with each dot representing a region of interest
(ROI) defined by peaks in the ARI and AFI (Figure 1B, see Experimental Procedures). Since
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thigh ARI and AFI represent focal events with high amplitude and recurrence, the well-known
signature events in GBM were grouped in the upper right as expected (Figure 1B, red circles).
The importance of focality in identifying candidate targets is highlighted by separation of ROIs
spanning MET or PTEN, driven by their high AFI, from the background of regional but highly
recurrent Chr7 gain or Chr10 loss, respectively (Figure 1B, clusters of blue dots correspond to
Chr7 and Chr10 ROIs, respectively). Moreover, infrequent but focal CNAs could be identified
on the GTS plots based on their high AFI score (y axis) despite low ARI (x axis), as were the
cases of infrequent but focal deletion of APAF1 and FBXW7, not previously described in GBM
(Figure 1B, green circles).
To rank the likely significance of GTS-defined ROIs, we calculated a GTS score reflecting the
combined contributions of ARI and AFI for each ROI and listed the top 50 rank-ordered
amplifications and deletions, respectively, in Table 1. Additionally, since copy number
aberration is a known mechanism to dysregulate expression, we generated RNA transcriptome
profiles on a subset of samples to identify those ROI-resident genes whose expression patterns
were concordant with their copy number. Here, we calculated a gene's gene weight (GW)
(Aguirre et al., 2004) (see Experimental Procedures) and considered those with p values less
than 0.05 as exhibiting copy-number-concordant expression (Table 1, in blue). By such GW
criteria, 30% of ROI-resident genes (26/80 in amplified ROIs; 16/58 in deleted ROIs) showed
copy-number-concordant expression, including all of the known signature events.
Interestingly, among those not exhibiting such concordance are FBXW7 and APAF1, pointing
to additional common mechanisms for their inactivation in GBM (see Discussion).
Codeletion of CDKN2C and CDKN2A via a Feedback Regulatory Circuit in Human GBM
The CDKN2C (p18INK4C) locus was identified by GTS as the top deletion peak in our data set
(Table 1). Focused analysis of the array-CGH profiles (Figure 1C) revealed a clearly defined
436 kb minimal common region delimited by a homozygous deletion of the p18INK4C locus in
a GBM cell line (solid lines), with slightly larger regions defined by CNAs detected in two
primary GBM specimens (dashed lines). That p18INK4C is the target of these deletions was
supported by finding that all 9 samples with this CNA showed reduction or loss of p18INK4C
RNA expression (Figure S1), and gene weight modeling confirmed copy-number-concordant
expression pattern for both p18INK4C probes (Figure 1C).
The observation of genomic deletion of p18INK4C was, at first glance, counterintuitive since
all samples sustaining the p18INK4C deletion (n = 9 of 46; p = 0.009, Fisher's exact test) also
harbored concurrent deletion of the CDKN2A/CDKN2B locus encompassing its related family
members, p16INK4A and p15INK4B. Survey of a panel of 747 human cancer cell lines of 32
anatomical origins for genomic status of CDKN2A (p16INK4A and p14ARF) and CDKN2C
revealed that codeletion of these two loci was observed predominantly in glioma tumor cell
lines (Table S3). Although protein expression by immunohistochemistry (IHC) does not inform
the mechanism of nonexpression (e.g., pathological inactivation by genomic deletion versus
normal physiological regulation), IHC analyses of p16INK4A and p18INK4C expressions on
GBM tissue microarrays containing an independent set of GBM tumor specimens confirmed
that a proportion of human GBM tumors (n = 10 of 59 informative cores) expressed low to
undetectable levels of both proteins (Figure S2 and Table S4). Additionally, resequencing of
p18INK4C in 53 human glioma cell lines (Table S5) identified three sequence variants of
p18INK4C in p16INK4A-deleted cell lines. While we cannot definitively rule out the possibility
that these represent rare germline variants without corresponding germline normal DNA, two
of these three nonsynonymous sequence variants, p.F37I in GB-1 and p.A61D in KNS-60,
targeted highly conserved or invariant amino acid residues (Figure S3).
Several lines of evidence suggest that the known principal RB pathway lesions in human tumors
act in a mutual exclusive manner (Sherr and McCormick, 2002). However, in the mouse, it has
Wiedemeyer et al. Page 4
Published as: Cancer Cell. 2008 April 08; 13(4): 355–364.
S
p
o
n
s
o
r
e
d
 
D
o
c
u
m
e
n
t
 
 
S
p
o
n
s
o
r
e
d
 
D
o
c
u
m
e
n
t
 
 
S
p
o
n
s
o
r
e
d
 
D
o
c
u
m
e
n
tbeen shown that loss of p18Ink4c and p16Ink4a can cooperate to induce pituitary tumor formation
(Ramsey et al., 2007), suggesting that p18Ink4c may have independent tumor suppressive
activity in a pathway parallel to that of its related family member p16Ink4a. Along the same
line, mice null for both p15Ink4b and p16Ink4a/Arf exhibited a broader tumor spectrum than mice
deficient for p16Ink4a/Arf alone (Krimpenfort et al., 2007). On the other hand, the presence of
an E2F binding site within the p18INK4C promoter (Blais et al., 2002) raised the possibility of
a regulatory loop, where inactivation of p16INK4A in nascent cancer cells triggers a
compensatory upregulation of p18INK4C via E2F, leading to genetic pressure for its concomitant
or subsequent deletion.
To explore this hypothesis of a feedback circuit involving p18INK4C via E2F1, we performed
chromatin immunoprecipitation and found that, in proliferating human astrocytes, the
activating E2F1 transcription factor was indeed bound physically to the p18INK4C promoter
(Figure 2A). Moreover, transient enforced expression of E2F1 in primary human astrocytes
led to a specific increase in p18INK4C RNA, but not the other three related INK4 CKIs
(Figure 2B). Acute suppression of p16Ink4a in immortalized (p53−/−) murine astrocytes resulted
in a significant induction of p18Ink4c protein (Figure 2C). Quantitative real-time RT-qPCR
demonstrated that this is at least in part due to regulation of transcription or message stability
because suppression of p16Ink4a by siRNA (siInk4a) resulted in a 2-fold increase of p18Ink4c
RNA compared to control cells transfected with nontargeting siRNA (siNT) (Figure 2D), an
effect that was maintained for up to 120 hr posttransfection (data not shown). Similarly, RT-
qPCR analysis of normal human astrocytes showed a 3.5-fold increase in p18INK4C expression
following p16INK4A knockdown (Figure 2D). A modest upregulation of p15INK4B was also
observed while p19INK4D was not induced upon p16INK4A knockdown. Taken together, these
data supported the view that a p16INK4A-E2F1-p18INK4C feedback circuit is operative in the
astrocytic lineage and underlies pressure for codeletion of these two related CKIs in GBM
tumors.
Functional Significance of p18INK4C Inactivation in p16INK4A-Deleted GBM Cells
To assess the functional significance of such a transcriptional feedback circuit, we asked
whether p18INK4C inactivation would further enhance the malignant properties of GBM
beyond those conferred by p16INK4A loss (Table 2). Here, we made use of two established
GBM cells, LN-18 and Hs683, which retain p18INK4C but lack p16INK4A. Using two shRNA
constructs capable of knocking down p18INK4C RNA by 45%–53% (Figure 3A), p18INK4C
depletion caused a 1.5- to 3.5-fold increase in anchorage-independent colonies in LN-18 and
Hs683, respectively (Figure 3A). These p18INK4C shRNAs had no effect on soft-agar formation
in p18INK4C-null LN-229 cells or in Cyclin D1/CDK4-amplified LN-Z308 cells, indicating that
the phenotypes are not due to nonspecific shRNA effects. Similar results were obtained using
synthetic p18INK4C siRNA oligos, where in the p16INK4A null and p18INK4C-WT cell lines
LN-18 and LN-444, 50% knockdown of p18INK4C increased soft agar colony formation 2- and
8-fold, respectively (Figure S4). Again, p18INK4C knockdown did not increase colony
formation in LN-Z308 cells (Table 2). Conversely, we examined the consequences of
p16INK4A and p18INK4C reconstitution in U87MG and LN-229, two established GBM cells
with concomitant deletions of the p16INK4A and p18INK4C loci as documented by copy number
profiling and/or qPCR (data not shown). As expected, comparable levels of enforced
expression of p16INK4A and p18INK4C in U87MG cells (Figure S5A) significantly inhibited
proliferation (Figures S5B and S5C) and anchorage-independent growth in vitro (Figure 3B;
Table 2). In contrast, enforced expression of p16INK4A or p18INK4C had no impact in LN-Z308
GBM cells with amplification and overexpression of Cyclin D1 and CDK4 and intact
p16INK4A and p18INK4C genomic loci) (Table 2; Figure 3B; Figure S5C).
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tThat the combined loss of p16INK4A and p18INK4C function confers enhanced malignant
potential over that associated with p16INK4A loss alone in human GBM cells was further
substantiated by demonstration that tumor-associated p18INK4C variants occurring at highly
conserved residues (p.F37I in GB-1 and p.A61D in KNS-60; Figure S3) were loss-of-function
mutants. Specifically, reconstitution of these variants in p18INK4C null cell lines imparted at
best 50% of suppressive activity of wild-type p18INK4C in both anchorage-independent growth
and cell proliferation assays (Figure 3C; Figure S6; data not shown). Mechanistically, we found
that the F37I and A61D variants did not bind CDK6 in coimmunoprecipitation studies
(Figure 3D), thus providing a molecular basis for the loss-of-function phenotype of these
mutant alleles.
Inactivation of p18Ink4c in p16Ink4a-Deficient Primary Astrocytes Conferred Tumorigenicity
The molecular evidence of compensatory regulation between p16Ink4a and p18Ink4c in
astrocytes suggested that complete deactivation of RB pathway tumor suppression activities
in this cell type will require concomitant inactivation of both CKIs. To directly address this
point, we compared in vivo tumorigenic potential of primary astrocytes that were inactivated
for p16Ink4a/Arf alone or for p16Ink4a/Arf and p18Ink4c. Here, we used lentivirally delivered
shRNA targeting p18Ink4c in primary nontransformed p16Ink4a/Arf−/− astrocytes to determine
whether inactivation of p18Ink4c bestowed oncogenicity to these nontumorigenic primary cells.
Reduction of p18Ink4c expression in already p16Ink4a-deficient primary astrocytes conferred
anchorage-independent growth in vitro and turmorigenicity in vivo (Figure 4). Specifically,
using two independent shRNA (data shown for one shRNA), near complete and stable
knockdown of p18Ink4c (Figure 4A inset) in primary p16Ink4a/Arf−/− astrocytes resulted in
enhanced anchorage-independent growth in semisolid medium in culture. When transplanted
subcutaneously into immunodeficient hosts, p18Ink4c-suppressed p16Ink4a/Arf−/− astrocytes
formed malignant tumors that were strongly Nestin-positive, in contrast to controlled
p16Ink4a/Arf−/− astrocytes which were not tumorigenic in vivo (Figures 4B and 4C). The
resultant tumors maintained low to absent p18Ink4c expression at the RNA and protein levels
(Figure 4D and data not shown). Enhanced in vivo tumorigenic phenotype upon p18Ink4c
suppression was similarly observed in astrocytes deficient for p16Ink4a/Arf and Pten
(Figure S7A). Furthermore, even in the presence of EGFRvIII oncogene, suppression of
p18Ink4c trended toward development of larger tumors from p16Ink4a/Arf−/− astrocytes
(Figure S7B). In conclusion, full transformation of primary astrocytes in a xenograft model
required inactivation of p18Ink4c in addition to that of p16Ink4a.
Discussion
In this report, we analyzed the copy number and expression profiles of human GBM cell lines
and tumors using a nonheuristic methodology called GTS. In addition to the well-known and
highly recurrent events, GTS defines and ranks many previously unrecognized CNAs, uncovers
frequent codeletion of two related CKI genes, CDKN2C and CDKN2A, in human cancers, and
implicates APAF1 and FBXW7 in glioma pathogenesis.
Recent data in the mouse have challenged the dogma of exclusivity on involvement of major
components of the CKI-CDK4/6-RB cell cycle regulatory axis in cancer. Ramsey et al. have
provided evidence that loss of p18Ink4c can result in upregulation of p16Ink4a in specific murine
tissues and that combined germline nullizygosity for both CKI facilitates the development of
pituitary tumors (Ramsey et al., 2007). Correspondingly, Krimpenfort et al. have established
compensatory p15Ink4b protein stabilization in p16Ink4a null mice, supporting a cooperative
tumor suppressor role for p15INK4B (Krimpenfort et al., 2007). Whether similar compensatory
mechanisms among members of the Ink4 family of CKI held for humans was uncertain,
particularly given the known cross-species differences in RB pathway regulation in the
development of normal and neoplastic cells (Gil and Peters, 2006; Kim and Sharpless, 2006).
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tHere, the collective genomic and functional evidence of this report provides the first
documentation of common coinactivation of multiple members of CKIs in human GBM via
genomic codeletion of the CDKN2A/B and CDKN2C loci or concurrent loss of protein
expression of p18INK4C and p16INK4A.
Importantly, the elucidation of underlying molecular circuitry driving above patterns of
inactivation provides new insight into RB pathway function in human cancer. By
demonstrating a p16INK4A-E2F-p18INK4C feedback circuit operative in the astrocytic cell
lineage, we provided molecular basis for “back-up” tumor suppressors such as p18INK4C. We
showed that p18INK4C backup tumor suppressor is engaged in the relatively common setting
of p16INK4A inactivation, resulting in enhanced proliferation and subsequent E2F-mediated
induction of p18INK4C expression, consequently leading to genetic pressure for subsequent
inactivation of p18INK4C. It is worth noting that, while its inactivation is necessitated, at least
in part, by its redundant role with p16INK4A in cell-cycle regulation, our results do not exclude
the possibility that p18INK4C may have additional functional activities beyond G1 CDK
inhibition driving its inactivation during gliomagenesis. On the basis of these data, we conclude
that p18INK4C is a bona fide tumor suppressor in human GBM and that a hierarchy of tumor
suppressive roles for members of the INK4 CKI exists, wherein p18INK4C likely serves as a
back-up to loss of p16INK4A. Such hierarchy of redundancy speaks further to the critical
importance of intact RB pathway function in constraining human tumorigenesis.
GTS is a computational methodology for copy number data that incorporates focality with
amplitude in context of frequency (recurrence) to determine likely significance of a given CNA.
The two scores computed in GTS, ARI and AFI, describe key features of CNA across samples
and provide highly complimentary information. ARI readily identifies genomic regions which
are recurrently altered while disregarding the focality of CNA events: common gain of
chromosome 7 and recurrent EGFR-region amplification are both identified as salient
alterations in GBM. AFI scoring further distinguishes genomic regions that are altered focally
versus regionally across samples, measuring the degree to which CNA is specifically targeting
each point in the genome. Thus, the two scores comprising GTS summarize the continuum of
CNA from wide regional alterations to the highly focal events, which may directly implicate
candidate targets. In this study, AFI and ARI were given equal weight in delimiting ROIs, thus
preferentially emphasizing high-amplitude focal aberrations over broader regional alterations;
such preference reflects the fact that the former is more readily amenable to downstream
workup, but not necessarily more important biologically.
The power of GTS lies in its ability to inform on focal but infrequent events that would
otherwise be lost in methodologies that consider mainly amplitude and recurrence. Indeed,
infrequent but focal CNAs can be highly informative as they may point to genes that are
activated or silenced by other means, such as deletions of APAF1 and FBXW7. APAF1 maps
to 12q22-23, a region associated with common LOH in GBM (Watanabe et al., 2003). APAF1
is a critical component of the apoptosome and caspase-9 activation (Li et al., 1997b).
Inactivation of this pathway has been implicated in GBM as highlighted by recent work
showing near universal upregulation of Bcl2L12, a regulator of apoptosis downstream of
APAF1 (Stegh et al., 2007). FBXW7 is a haplo-insufficient tumor suppressor gene (Mao et al.,
2004) recently shown to be frequently inactivated in T cell lymphomas by mutation or deletion
(Malyukova et al., 2007; Maser et al., 2007). As it encodes an F-box protein that is part of the
ubiquitin protein ligase complex, FBXW7 has many known glioma-relevant client proteins
including cyclin E, c-Myc, Aurora-A, Notch, and c-Jun. In addition to a large body of literature
implicating the Myc network in GBM (Bredel et al., 2005), as well as presence of MYC
amplification in GBM (Table 1, no. 6), FBXW7 expression itself has recently been correlated
with GBM patient survival (Hagedorn et al., 2007) although a direct pathogenetic role in GBM
has not been established. Interestingly, FBXW7 and APAF1 do not exhibit copy number-driven
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texpression profiles among GBM tumors, consistent with their infrequent occurrence, thus
pointing to alternative more common mechanisms for their inactivation in GBM. Accordingly,
APAF1 has been known to be inactivated by methylation (Soengas et al., 2001) and FBXW7
by inactivating point mutations (Moberg et al., 2001). These findings of infrequent but focal
deletion coupled with non-copy-number-concordant expression pattern should motivate direct
examination of the mechanism and roles of APAF1 and FBXW7 inactivation in GBM.
The GBM oncogenome is highly complex and harbors numerous CNAs, many of which
presumably target yet-to-be-discovered GBM cancer genes. We have demonstrated here that
GTS can address one critical need in the development of a functional map of GBM genetic
targets: namely, to prioritize those genomic alterations that are likely to be of importance from
among those that are more likely to be bystanders of the cancer process. In particular, GTS has
prioritized 100 top-ranking ROIs, encompassing a total of only 138 resident genes representing
a limited list of candidates for downstream functional validation. Among these 138 candidates
are 42 that exhibited significant copy number-concordant expression patterns, including 10
validated GBM genes, pointing to high probability of biological relevance for the remaining
32 GW-significant candidates residing within these ROIs. On the other hand, as exemplified
by APAF1 and FBXW7, non-GW-significant residents may also represent targets of rare
genomic events that are more commonly dysregulated by other mechanisms, rendering them
similarly productive entry points for identification of mutations or epigenetic alterations.
Downstream functional validation of these high probability candidates should yield novel
GBM genes and potential targets for therapeutic intervention.
Experimental Procedures
Cell Lines and Tumors
Frozen tumor specimens (Table S1A) were obtained from the Memorial Sloan-Kettering
Cancer Center tumor bank. All tumor specimens were collected after obtaining written
informed consent preoperatively. This study was approved by the Institutional Review Board
of the hospital. Each tumor was confirmed histopathologically to be grade IV glioblastoma.
Glioma cell lines (Table S1B) were propagated in RPMI-1640 medium supplemented with
10% FBS and penicillin/streptomycin/amphotericin B. Normal human astrocytes were
obtained from ScienCell and Cambrex and propagated in astrocyte medium (ScienCell).
Murine astrocytes were propagated in DMEM supplemented with 10% FBS and penicillin/
streptomycin/amphotericin B. DNA from tumors and cell lines was isolated with DNeasy
(QIAGEN). RNA was isolated with Trizol (Invitrogen), digested with DNase (Promega), and
purified with RNeasy (QIAGEN). siRNAs were purchased from Dharmacon and transfected
using Lipofectamine 2000 (Invitrogen). Normal human brain RNA was purchased from
Ambion.
Proliferation and Tumorigenicity Assays
Soft agar assays were performed in duplicate or triplicate in 6-well plates. 5000 cells per well
were seeded in regular medium containing 0.4% low-melting agarose on bottom agar
containing 1% low-melting agarose in regular medium. After 14 days, colonies were stained
with Iodonitrotetrazoliumchloride (Sigma) and counted. For bromodeoxyuridine (BrdU)
labeling, cells were incubated with 10 μM BrdU (Sigma) in regular medium for 30 min. Cells
were then ethanol-fixed, RNase-digested, and incubated with anti-BrdU (DAKO), followed
by a FITC-labeled secondary antibody (DAKO) counterstained with propidium iodide and
analyzed by flow cytometry. For in vivo tumorigenicity assays, 106 genetically engineered
astrocytes comixed with matrigel (Sigma) were transplanted subcutaneously into flanks of Ncr
nude mice (Taconic) and followed for tumor development. Tumor size was measured by caliper
by the same operator over time. At termination of the experiment, tumors were harvested and
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tprocessed for pathological and molecular analyses. All animal experiments were approved by
Harvard's Institutional Animal Care and Use Committee (IACUC). Statistical analysis was
performed with a Student's t test.
Expression Analysis
Protein (10–30 μg) was resolved on 4%–12% Bis-Tris gradient gels (Invitrogen), transferred
to a PVDF membrane (Perkin Elmer), and incubated with antibodies against p18INK4C (mouse
monoclonal antibody, Cell Signaling; rabbit polyclonal antibody, LabVision), tubulin (Sigma),
vinculin (Santa Cruz), and Flag epitope (Sigma). Quantitative PCR was performed on an
Mx3000P cycler (Stratagene) using QuantiTect SYBR green (QIAGEN). Primers were
obtained from SuperArray. Reactions were performed as triplicates or quadruples for both test
and control primers. Relative expression was calculated with the ΔΔCt method. Reverse
transcription was performed with Superscript II (Invitrogen) and oligo-dT priming.
Immunoprecipitation was carried out using standard techniques. One milligram of cell lysate
was incubated with 2 μg of CDK6 antibody (Santa Cruz) overnight.
Retroviral Constructs
INK4A and INK4C cDNAs were PCR-amplified from pCMV-p18 (Dr. Y. Xiong) and pFlag-
p16 (Dr. C. Geisen) and cloned into pBabe-puro3 as both untagged and as Flag fusions.
INK4C point mutations were introduced using QuikChange II (Stratagene). Three shRNA
sequences were annealed (sequences available upon request) and cloned into pSuperRetroPuro
(Oligoengine). Retrovirus was produced in Phoenix A cells, and target cells were infected at
48 hr and 72 hr past transfection in the presence of 5 μg/ml polybrene (Sigma). Infected cells
were selected with 2.5 μg/ml puromycin for 4 days before being assayed. Lentiviral shRNA
constructs targeting GFP and p18INK4C were obtained through the RNAi Consortium (TRC).
Sequences are available from their website.
Resequencing
GBM cell line DNAs were sequenced as previously described (Davies et al., 2005) by direct
sequencing of each exon with intronic flanking sequences utilizing ABI big dye chemistry on
ABI3730 machines. Each variant was confirmed in three independent sequencing assays.
Primer sequences are available upon request.
Array-CGH
Genomic DNA was processed, labeled, and hybridized onto Agilent's 60-mer array-CGH
microarrays with 44K or 244K density (for performance comparison, see (Greshock et al.,
2007) according to manufacturer's protocol. Processing of array-CGH data to generate a
segmented profile by circular binary segmentation (CBS) (Lai et al., 2005; Venkatraman and
Olshen, 2007) was as detailed elsewhere (Aguirre et al., 2004). Complete profiles are deposited
on the GEO website under super-series accession no. GSE9200
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9200).
Genome Topography Scanning
GTS is performed in two stages, starting with array-CGH data which has been smoothed by
CBS: (1) calculation of ARI and AFI for each aCGH probe position in the genome, followed
by (2) identification of local peaks in the combined GTS scores (ARI∗AFI). Separate ARI and
AFI are calculated for gain and loss. ARI is computed for each probe position as the mean of
CBS-smoothed log2 ratios across all samples showing chromosomal gain, and then likewise
for all samples showing loss. A focality-weighted ARI (fwARI) is calculated for gain and loss
similarly to ARI, but after weighting the smoothed log2 ratio at each probe position by the
number of genetic elements (genes, microRNAs, etc.) spanned by the CNA event, accounting
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tfor linkage of CNA across multiple CBS segments (see Supplemental Experimental
Procedures). AFI is the ratio of fwARI/ARI. To identify focal CNA events, regions of interest
(ROIs) are then defined by bounding local peaks in the combined GTS scores (ARI∗AFI,
equivalent to fwARI, see Supplemental Experimental Procedures). In this analysis of GBM
data set, log2 ratio was used directly in the calculation of ARI and equal weighting was applied
to each genetic element (RefSeq gene list) for the AFI score. Transformation of copy number
and differential weighting of genetic elements may be utilized depending on the application.
GTS algorithm is available as an R package at http://cbio.mskcc.org/brennan and is in the
process of being submitted to BioConductor.
Expression Profiling and Gene Weight Significance Calculation
RNA expression profiling was performed at the Dana-Farber Microarray Core facility using
the U133Plus2.0 chip (Affymetrix). Gene weight (GW) was calculated as previously described
(Aguirre et al., 2004; Carrasco et al., 2006; Hyman et al., 2002). Briefly, for each gene probe
set, GW of expression values for test set “T” compared to reference set “R” is calculated by:
where test and reference sets are defined by presence or absence, respectively, of CNA in the
chromosomal region including the gene. Chromosomal amplifications are tested separately
from deletions. Significance was determined by permuting sample labels for expression data
(1000 permutations, p value ≤ 0.05). Genes with GW significance are considered exhibiting
“copy number concordant expression.”
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was carried out using the EZ ChIP kit per
manufacturer's protocol (Upstate). Briefly, genomic DNA from 5 × 106 normal human
astrocytes was formaldehyde crosslinked and sonicated in 300 μl of lysis buffer until the
average DNA fragment length was 600 bp. One-hundred microliters of lysate, diluted 10-fold
in ChIP dilution buffer, was used per IP reaction. Antibodies used were anti-E2F1 (Santa Cruz,
sc-193), anti-RB (Santa Cruz, sc-50), and rabbit control IgG (NeoMarkers, NC-100-P).
INK4C and ACTNB promoter fragments were amplified as described (Blais et al., 2002).
Accession Numbers
Complete profiles are deposited on the GEO website under super series accession no. GSE9200
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9200).
Supplemental Data
Refer to Web version on PubMed Central for supplementary material.
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Analyses of GBM Oncogenome by GTS Identified CDKN2C Deletion
(A) Skyline profile of GBM oncogenome with ARI on y axis. AFI is represented by color scale
based on percentile rank, highlighting the most focally altered regions.
(B) Two-dimensional GTS plots of log(ARI) (x axis) and log(AFI) (y axis) for amplification
(left) and deletion (right). Black outer circles mark ROIs ranked among top 50 by GTS scores
(Table 1). Red circles mark ROIs spanning signature events. ROIs on frequently gained chr7
are marked in blue on the amplification plot. Similarly, ROIs on chr10 are marked in blue on
the deletion plot. Note separation of MET or PTEN from Chr7 or Chr10 events, respectively.
(C) Deletion ROI spanning CDKN2C is present in 4/28 glioblastoma tumor samples (two
examples shown), defining a focal minimal common region of deletion of 2Mbp (dashed lines).
Homozygous deletions are common in glioma cell lines (5/18) and further refine the minimal
common region of deletion to p18INK4C (solid lines). Analysis of copy-number-concordant
expression by gene weight modeling (see Experimental Procedures) demonstrates highly
significant coordinate loss of p18INK4C expression in tumors and cell lines that show
chromosomal deletion. Gene weights for both probe sets for p18INK4C are significant at p <
0.01 (black circles). GW Sig, gene weight significance.
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Acute Suppression of p16INK4A Results in Compensatory Upregulation of p18INK4C
(A) E2F transcription factors bind the p18INK4C promoter in human astrocytes. A p18INK4C
promoter DNA fragment was immunoprecipitated with anti-E2F1, but not with the control or
an RB1 antibody. (B) Human astrocytes were transiently transfected with empty vector or
expression constructs for E2F1 and E2F5. INK4 and CCNE1 RNA expression was analyzed
by RT-qPCR at 72 hr after transfection and normalized to GAPDH expression. Vector
transfected cells were set to 1 for each transcript. E2F1, but not E2F5, specifically increased
p18INK4C (INK4C) RNA to a similar extent as the well-characterized E2F target CCNE1. Error
bars represent mean ± standard deviation.
(C) Astrocytes from p53−/− mice at passage 2 were transfected with nontargeting siRNA (siNT)
or siRNA targeting p16Ink4a (siInk4a) and assayed for p18Ink4c protein expression at 72 hr after
transfection. Loading control, vinculin.
(D) Murine p53−/− astrocytes and normal primary human astrocytes were transfected with
siNT or siInk4a and assayed for RNA expression levels of p16Ink4a (Ink4a), p15Ink4b (Ink4b),
p18Ink4c (Ink4c), and p19Ink4d (Ink4d) by RT-qPCR at 72 hr posttransfection. Relative levels
compared to Ink4 expression of siNT-transfected cells are shown after normalization to
Gapdh. Error bars represent mean ± standard deviation.
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p18INK4C Inactivation in p16INK4A Null GBM Cell Lines Enhances Tumorigenicity
(A) GBM cells, LN-229 (p16INK4A/p18INK4C null), LN-18, Hs683 (both p16INK4A null,
p18INK4C WT), and LN-Z308 (p16INK4A/p18INK4C WT, CDK4/Cyclin D1-amplified) infected
with retroviral expression constructs for small hairpins targeting p18INK4C (shINK4C-2 and
shINK4C-5) or a nontargeting hairpin (shNT) were scored for colony formation in soft agar at
day 14 and plotted as percentage of shNT controls. Error bars represent standard deviation of
duplicates. Suppression of p18INK4C significantly increased the number of colonies in LN-18
(p = 0.01 and p = 0.006 for shINK4C-2 and shINK4C-5, respectively) and Hs683 (p = 0.07
and p = 0.004 for shINK4C-2 and shINK4C-5, respectively). Degrees of p18INK4C knockdown
were determined by RT-qPCR relative to shNT-infected cells (100%) and indicated in the
bottom table. Error bars represent mean ± standard deviation.
(B) p16INK4A/p18INK4C null GBM lines U87MG and LN-229 as well as p16INK4A/p18INK4C
WT, CDK4/Cyclin D1-amplified LN-Z308 stably infected with retroviral expression
constructs for Flag-tagged p16INK4A (INK4AFLAG), Flag-tagged p18INK4C (INK4CFLAG),
WT p18INK4C (INK4C), or empty vector (Vector) were assayed for colony formation in soft
agar. Soft agar colonies were stained and counted at day 14 and plotted as percentage ± standard
deviation relative to vector-infected cells (U87MG-Vector 100%, U87MG-INK4CFLAG 23 ±
2% [p = 0.0005], U87MG-INK4AFLAG 18 ± 2% [p = 0.0003]; LN-229-Vector 100%, LN-229-
INK4CFLAG 23 ± 3% [p = 0.0002], LN-229-INK4AFLAG 11 ± 2% [p=0.0001]). The scale bar
indicates 2 mm.
(C) GBM cell lines LN-229 (p16INK4A/p18INK4C null), LN-444, LN-18 (both p16INK4A null,
p18INK4C WT), and LN-Z308 (p16INK4A/p18INK4C WT, CDK4/Cyclin D1-amplified) infected
with vector control (Vector), WT p18INK4C (INK4C), or p18INK4C variants (F37I and A61D)
were assayed for soft-agar colony formation, as in (B). Both p18INK4C variants exhibited
reduced capability of repressing colony formation. Error bars represent mean ± standard
deviation.
(D) Stable LN-229 cell populations were derived as in (C). Wild-type, but not mutant,
p18INK4C coimmunoprecipitated with CDK6 (p18INK4C bands are marked by asterisks). The
same effect was observed with binding to CDK4, albeit interaction between wild-type
p18INK4C and CDK4 was much weaker (data not shown).
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p16Ink4a and p18Ink4c Coinactivation Confers Tumorigenicity to Murine Astrocytes
(A) Murine p16Ink4a/ARF null astrocytes were infected with lentiviral shRNA expression
constructs targeting GFP (shGFP) or p18Ink4c (shInk4c). Knockdown of p18Ink4c resulted in
drastically lower p18Ink4c protein levels (loading control, vinculin) and significantly higher
colony formation in soft agar (error bars indicate mean ± standard deviation of quadruples).
(B) Stable astrocyte populations derived as in (A) were subcutaneously injected into Ncr nude
mice. While p18Ink4c-deprived cells formed tumors within 2 weeks, control cells did not
generate tumor (mean ± standard deviation plotted). Injection sites of control mice were
histologically confirmed to be tumor free.
(C) Tumors derived from shInk4c-infected astrocytes displayed malignant anaplastic histology
and a high mitotic rate by H&E staining. Immunohistochemical analysis confirmed expression
of the neural marker Nestin in a pattern similar to human astrocytomas. The scale bar indicates
30 μm.
(D) Matrigel-embedded shGFP-infected astrocytes and tumor-derived shInk4c-infected
astrocytes were assayed for p18Ink4c RNA expression relative to Gapdh expression confirming
stable p18Ink4c knockdown in tumor cells. Error bars indicate mean ± standard deviation.
Wiedemeyer et al. Page 17
Published as: Cancer Cell. 2008 April 08; 13(4): 355–364.
S
p
o
n
s
o
r
e
d
 
D
o
c
u
m
e
n
t
 
 
S
p
o
n
s
o
r
e
d
 
D
o
c
u
m
e
n
t
 
 
S
p
o
n
s
o
r
e
d
 
D
o
c
u
m
e
n
tS
p
o
n
s
o
r
e
d
 
D
o
c
u
m
e
n
t
 
 
S
p
o
n
s
o
r
e
d
 
D
o
c
u
m
e
n
t
 
 
S
p
o
n
s
o
r
e
d
 
D
o
c
u
m
e
n
t
Wiedemeyer et al. Page 18
Table 1
GTS Rank-Ordered ROIs
List of top 50 amplified (left) and deleted (right) ROIs, respectively, rank-ordered by GTS scores. ROI resident genes with gene-weight significance
(p < 0.05) are highlighted in blue. Italics mark genes not represented on the expression array. Known GBM signature genes are in bold.
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Table 2
Summary of p18INK4C Gain-of-Function and Loss-of-Function Studies
Tumorigenicity (Soft Agar Growth)
CDKN2A p18
INK4C CCND1/CDK4 p18
INK4C Expression p18
INK4C KD
LN-18 null WT WT decrease increase
LN-444 null WT WT decrease increase
Hs683 null WT WT N/A increase
LN-229 null null WT decrease no change
U87MG null null WT decrease N/A
LN-Z308 WT WT amp no change no change
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